BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $200,278 | -7.6% | 2,942 | +10.8% | 0.05% | -11.5% |
| Q2 2023 | $216,822 | +17.5% | 2,656 | +6.8% | 0.05% | +4.0% |
| Q1 2023 | $184,518 | -10.4% | 2,487 | +0.1% | 0.05% | -15.3% |
| Q4 2022 | $205,959 | +17.7% | 2,485 | +302.1% | 0.06% | +5.4% |
| Q3 2022 | $175,000 | -11.2% | 618 | +8.8% | 0.06% | -6.7% |
| Q2 2022 | $197,000 | -16.5% | 568 | +4.2% | 0.06% | -4.8% |
| Q1 2022 | $236,000 | -20.8% | 545 | -5.5% | 0.06% | -14.9% |
| Q4 2021 | $298,000 | 0.0% | 577 | -6.0% | 0.07% | -15.9% |
| Q3 2021 | $298,000 | +18.3% | 614 | +9.8% | 0.09% | +20.5% |
| Q2 2021 | $252,000 | +22.3% | 559 | +3.7% | 0.07% | +17.7% |
| Q1 2021 | $206,000 | +12.6% | 539 | -6.4% | 0.06% | +8.8% |
| Q4 2020 | $183,000 | +36.6% | 576 | +6.3% | 0.06% | +21.3% |
| Q3 2020 | $134,000 | -15.7% | 542 | -9.8% | 0.05% | -9.6% |
| Q2 2020 | $159,000 | +42.0% | 601 | +1.9% | 0.05% | +23.8% |
| Q1 2020 | $112,000 | -16.4% | 590 | -3.6% | 0.04% | +7.7% |
| Q4 2019 | $134,000 | +15.5% | 612 | +3.0% | 0.04% | +2.6% |
| Q3 2019 | $116,000 | -8.7% | 594 | -2.6% | 0.04% | -7.3% |
| Q2 2019 | $127,000 | +9.5% | 610 | +4.3% | 0.04% | +5.1% |
| Q1 2019 | $116,000 | +33.3% | 585 | -2.7% | 0.04% | +25.8% |
| Q4 2018 | $87,000 | -24.3% | 601 | +6.7% | 0.03% | -22.5% |
| Q3 2018 | $115,000 | +38.6% | 563 | 0.0% | 0.04% | +29.0% |
| Q2 2018 | $83,000 | +2.5% | 563 | +4.5% | 0.03% | 0.0% |
| Q1 2018 | $81,000 | +3.8% | 539 | -10.3% | 0.03% | +6.9% |
| Q4 2017 | $78,000 | 0.0% | 601 | -6.5% | 0.03% | -3.3% |
| Q3 2017 | $78,000 | 0.0% | 643 | -3.6% | 0.03% | -6.2% |
| Q2 2017 | $78,000 | +14.7% | 667 | -0.7% | 0.03% | +10.3% |
| Q1 2017 | $68,000 | -2.9% | 672 | -1.5% | 0.03% | -6.5% |
| Q4 2016 | $70,000 | -6.7% | 682 | -0.3% | 0.03% | -8.8% |
| Q3 2016 | $75,000 | -5.1% | 684 | -2.7% | 0.03% | -10.5% |
| Q2 2016 | $79,000 | +19.7% | 703 | 0.0% | 0.04% | +15.2% |
| Q1 2016 | $66,000 | 0.0% | 703 | -4.4% | 0.03% | 0.0% |
| Q4 2015 | $66,000 | -2.9% | 735 | -0.1% | 0.03% | -15.4% |
| Q3 2015 | $68,000 | – | 736 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |